HuidaGene Therapeutics
PrivateLast Round
Series C
May 1, 2022
Company Overview
HuidaGene Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series C round in May 2022.
HuidaGene Therapeutics is a biotechnology company that develops CRISPR-based gene-editing and RNA-targeting therapies for the treatment of severe genetic diseases in neurology, ophthalmology, and neuromuscular fields.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HuidaGene Therapeutics Comparables
Compare HuidaGene Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| YolTech Therapeutics | 83% | |
| Neurophth | 81% | |
| 北京中因科技有限公司 | 80% |
For institutional investors. Book with your work email.
HuidaGene Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 1, 2022 | ||||
| Series B | May 1, 2021 | ||||
| Series A | Nov 1, 2019 | ||||
| Angel | Nov 1, 2018 |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 7, 2025
Monthly visitors grew 245% MoM to 6.9K.
- May 1, 2022
Raised Series C round
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 20, 2026
HuidaGene tests a gene-editing treatment for Duchenne muscular dystrophy in China, while experts question the approach's safety and the transparency of trial disclosures after a patient dies on Aug 19th '26.
For institutional investors. Book with your work email.
HuidaGene Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HuidaGene Therapeutics's valuation, stock price, and market status.
Is HuidaGene Therapeutics a public or private company?
HuidaGene Therapeutics is a private company.
What is the current stock price of HuidaGene Therapeutics?
HuidaGene Therapeutics is a private company, so its shares have no public market price. Caplight tracks HuidaGene Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HuidaGene Therapeutics worth (valuation)?
Valuation information for HuidaGene Therapeutics is not publicly available.
Can I buy HuidaGene Therapeutics stock?
HuidaGene Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HuidaGene Therapeutics's last funding round?
HuidaGene Therapeutics's most recent funding round was Series C on May 1, 2022.
Who are the main investors in HuidaGene Therapeutics?
Investor information for HuidaGene Therapeutics is not publicly disclosed.
Will HuidaGene Therapeutics IPO soon?
No public IPO plans have been announced for HuidaGene Therapeutics.
How can I track HuidaGene Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in HuidaGene Therapeutics's shares on secondary markets.